BR112017017411A2 - Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida - Google Patents
Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamidaInfo
- Publication number
- BR112017017411A2 BR112017017411A2 BR112017017411A BR112017017411A BR112017017411A2 BR 112017017411 A2 BR112017017411 A2 BR 112017017411A2 BR 112017017411 A BR112017017411 A BR 112017017411A BR 112017017411 A BR112017017411 A BR 112017017411A BR 112017017411 A2 BR112017017411 A2 BR 112017017411A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxazepin
- carboxamide
- oxo
- benzyl
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- -1 oxazepin-3-yl Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
- C07C223/04—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115674P | 2015-02-13 | 2015-02-13 | |
| PCT/IB2016/050755 WO2016128936A1 (en) | 2015-02-13 | 2016-02-12 | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017411A2 true BR112017017411A2 (pt) | 2018-04-03 |
Family
ID=55359562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017411A BR112017017411A2 (pt) | 2015-02-13 | 2016-02-12 | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10287280B2 (enExample) |
| EP (1) | EP3256467A1 (enExample) |
| JP (1) | JP2018505199A (enExample) |
| KR (1) | KR20170117472A (enExample) |
| CN (1) | CN107207485A (enExample) |
| AU (1) | AU2016217496B2 (enExample) |
| BR (1) | BR112017017411A2 (enExample) |
| CA (1) | CA2976172A1 (enExample) |
| IL (1) | IL253731A0 (enExample) |
| RU (1) | RU2017131862A (enExample) |
| WO (1) | WO2016128936A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10787462B2 (en) | 2015-10-23 | 2020-09-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TWI781920B (zh) | 2016-02-05 | 2022-11-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| WO2019123219A1 (en) * | 2017-12-20 | 2019-06-27 | Glaxosmithkline Intellectual Property Development Limited | Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| JP2021523226A (ja) | 2018-05-03 | 2021-09-02 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 |
| US10975064B2 (en) | 2018-05-03 | 2021-04-13 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| CA3139631A1 (en) * | 2019-05-17 | 2020-11-26 | Glaxosmithkline Intellectual Property Development Limited | Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| PH12022550537A1 (en) | 2019-09-06 | 2023-03-20 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same. |
| BR112022002580A2 (pt) | 2019-09-06 | 2022-07-19 | Rigel Pharmaceuticals Inc | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos |
| FI4055021T3 (fi) | 2019-11-07 | 2025-12-16 | Rigel Pharmaceuticals Inc | Heterosyklisiä rip1:tä estäviä yhdisteitä |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI638815B (zh) | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
-
2016
- 2016-02-12 EP EP16704713.3A patent/EP3256467A1/en not_active Withdrawn
- 2016-02-12 BR BR112017017411A patent/BR112017017411A2/pt not_active Application Discontinuation
- 2016-02-12 KR KR1020177025358A patent/KR20170117472A/ko not_active Withdrawn
- 2016-02-12 CN CN201680010191.7A patent/CN107207485A/zh active Pending
- 2016-02-12 CA CA2976172A patent/CA2976172A1/en not_active Abandoned
- 2016-02-12 AU AU2016217496A patent/AU2016217496B2/en not_active Ceased
- 2016-02-12 WO PCT/IB2016/050755 patent/WO2016128936A1/en not_active Ceased
- 2016-02-12 RU RU2017131862A patent/RU2017131862A/ru not_active Application Discontinuation
- 2016-02-12 US US15/548,500 patent/US10287280B2/en active Active
- 2016-02-12 JP JP2017542048A patent/JP2018505199A/ja active Pending
-
2017
- 2017-07-30 IL IL253731A patent/IL253731A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3256467A1 (en) | 2017-12-20 |
| KR20170117472A (ko) | 2017-10-23 |
| US20180022737A1 (en) | 2018-01-25 |
| IL253731A0 (en) | 2017-09-28 |
| CA2976172A1 (en) | 2016-08-18 |
| AU2016217496B2 (en) | 2019-03-07 |
| JP2018505199A (ja) | 2018-02-22 |
| US10287280B2 (en) | 2019-05-14 |
| RU2017131862A (ru) | 2019-03-13 |
| AU2016217496A1 (en) | 2017-08-17 |
| CN107207485A (zh) | 2017-09-26 |
| RU2017131862A3 (enExample) | 2019-06-06 |
| WO2016128936A1 (en) | 2016-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017017411A2 (pt) | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida | |
| IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
| MX390014B (es) | Compuestos de dinucleótidos cíclicos y métodos de uso. | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| BR112016020618A2 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
| MX2018014154A (es) | Polinucleotidos moduladores. | |
| MX374012B (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. | |
| HUE051877T2 (hu) | Biciklusos származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények | |
| HUE049507T2 (hu) | Új piperidinil származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények | |
| HUE062277T2 (hu) | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása | |
| CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| ECSP17030878A (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| BR112017003219A2 (pt) | formulação de acetato de abiraterona e métodos de uso | |
| BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| BR112019003987A2 (pt) | formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| ES2837136R1 (es) | Proceso para la preparación de 3alfa-hidroxi-5alfa-pregnan-20-ona (Brexanolona) | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| HUE059216T2 (hu) | Készítmény és eljárás annak elõállítására | |
| EP3373910A4 (en) | ECHINOMYCIN FORMULATIONS, METHOD FOR THE PREPARATION AND METHOD FOR USE THEREOF | |
| HUE056260T2 (hu) | Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására | |
| UY40794A (es) | Formas cristalinas de (s)-afoxolaner | |
| MX2018013573A (es) | Ciertos inhibidores de la proteína cinasa. | |
| BR112017012646A2 (pt) | Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 413/12 Ipc: C07D 413/12 (2006.01), A61K 31/553 (2006.01), A61P |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |